TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06752356: A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sponsor: Kedrion S.p.A. · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 161 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$17,630,720

Rescue Site Savings

+$11,625,256

Unlock Full NCT06752356 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06752356 Rescue Dossier →